| Identification | Back Directory | [Name]
(5Z)-5-[(5-phenylfuran-2-yl)methylidene]-3-prop-2-enyl-2-sulfanylidene-1,3-thiazolidin-4-one | [CAS]
851305-26-5 | [Synonyms]
LJ 001
(LJ001
(Z)-3-Allyl-5-((5-phenylfuran-2-yl)methylene)-2-thioxothiazolidin-4-one
4-Thiazolidinone, 5-[(5-phenyl-2-furanyl)methylene]-3-(2-propen-1-yl)-2-thioxo-, (5Z)-
(5Z)-5-[(5-phenylfuran-2-yl)methylidene]-3-prop-2-enyl-2-sulfanylidene-1,3-thiazolidin-4-one | [Molecular Formula]
C17H13NO2S2 | [MDL Number]
MFCD02120352 | [MOL File]
851305-26-5.mol | [Molecular Weight]
327.42 |
| Chemical Properties | Back Directory | [Boiling point ]
477.3±55.0 °C(Predicted) | [density ]
1.37±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
-2.83±0.20(Predicted) | [color ]
Yellow to orange |
| Hazard Information | Back Directory | [Uses]
LJ001 is a broad-spectrum and orally active antiviral agent. LJ001 exerts antiviral activities by binding to viral membranes. LJ001 inhibits TGEV and PDCoV infection. LJ001 decreases TGEV N and PDCoV N-protein expression[1][2]. | [in vivo]
LJ001 (20, 50 mg/kg; oral gavage or i.p.; daily for 7 days) shows no toxicity in mouse[2]. | Animal Model: | Female BALB/c mice[2] | | Dosage: | 20, 50 mg/kg | | Administration: | Oral gavage or i.p.; daily for 7 days | | Result: | Revealed no abnormalities except a slight elevation in serum cholesterol levels in the treated vs. vehicle control group. |
| [References]
[1] Zhang Y, et al. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro. Virus Res. 2020 Nov;289:198167. DOI:10.1016/j.virusres.2020.198167
[2] Wolf MC, et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A. 2010 Feb 16;107(7):3157-62. DOI:10.1073/pnas.0909587107 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|